In this episode, I interview Audrey Greenberg, Co-Founder and Chief Business Officer of the Center for Breakthrough Medicines (CBM), an innovative organization specializing in cell and gene therapy-focused contract development and manufacturing (CDMO).
CBM offers an integrated and comprehensive service, providing a one-source solution to accelerate the market delivery of advanced therapies. Their client-driven approach, combined with a patient-centric culture, ensures high quality and reliability in process and analytical development, viral vector manufacturing, GMP testing, cell therapy bioprocessing, plasmid production, and cell banking services, covering a product’s full life cycle.
CBM supports pharmaceutical and biotechnology clients throughout the entire advanced therapy process, from research and development to manufacturing and commercialization.
Audrey brings extensive experience from her background in accounting, finance, investment banking, and private equity. She has played a pivotal role in building CBM, focusing on recruiting top talent and securing significant investment, while emphasizing hard work, perseverance, and the importance of establishing trust with clients.
In 2022, SK pharmteco invested $350 million in CBM, and in September, SK announced the acquisition of a controlling interest in CBM. This move adds CBM’s extensive cell and gene therapy expertise to the SK pharmteco portfolio, furthering their strategy to provide end-to-end, multi-modality support for clients.
Tune in to hear Audrey Greenberg discuss her journey in co-founding CBM, the valuable lessons learned, the challenges faced by the industry, and how CBM is at the forefront of cell and gene therapy manufacturing.
In this episode, I interview Audrey Greenberg, Co-Founder and Chief Business Officer of the Center for Breakthrough Medicines (CBM), an innovative organization specializing in cell and gene therapy-focused contract development and manufacturing (CDMO).
CBM offers an integrated and comprehensive service, providing a one-source solution to accelerate the market delivery of advanced therapies. Their client-driven approach, combined with a patient-centric culture, ensures high quality and reliability in process and analytical development, viral vector manufacturing, GMP testing, cell therapy bioprocessing, plasmid production, and cell banking services, covering a product’s full life cycle.
CBM supports pharmaceutical and biotechnology clients throughout the entire advanced therapy process, from research and development to manufacturing and commercialization.
Audrey brings extensive experience from her background in accounting, finance, investment banking, and private equity. She has played a pivotal role in building CBM, focusing on recruiting top talent and securing significant investment, while emphasizing hard work, perseverance, and the importance of establishing trust with clients.
In 2022, SK pharmteco invested $350 million in CBM, and in September, SK announced the acquisition of a controlling interest in CBM. This move adds CBM’s extensive cell and gene therapy expertise to the SK pharmteco portfolio, furthering their strategy to provide end-to-end, multi-modality support for clients.
Tune in to hear Audrey Greenberg discuss her journey in co-founding CBM, the valuable lessons learned, the challenges faced by the industry, and how CBM is at the forefront of cell and gene therapy manufacturing.